A significant increase in tumour infiltrating CD8+ T cells was also observed in one patient when comparing pre- and post-treatment tissue, in a phase 1b trial studying the safety of recombinant PV lerapolturev (formerly known as PVSRIPO) in recurrent paediatric HGG [18]. This evidence concerns the gene CD8A and neoplasm.